Vascular re-entry device

Information

  • Patent Grant
  • 11191554
  • Patent Number
    11,191,554
  • Date Filed
    Tuesday, June 11, 2019
    5 years ago
  • Date Issued
    Tuesday, December 7, 2021
    2 years ago
Abstract
A method for operating an ultrasonic reentry device, includes: providing an ultrasound transmission member having a proximal end and a distal end; providing a catheter body having a lumen surrounding the ultrasound transmission member; providing a dilator slidably disposed within the lumen of the catheter body, the dilator surrounding the ultrasound transmission member; and exposing the distal end of the ultrasound transmission member from a distal end of the dilator.
Description
BACKGROUND OF THE INVENTION

There are many procedures and systems for treating vascular or venous obstructions that are occluded with atheroma, plaque, calcific material, and the like. Such obstructions are often referred to as vascular chronic total occlusions. Total occlusions can be treated, for example, by a surgical bypass procedure or a catheter-based intervention such as angioplasty.


Catheter-based intervention procedures may require the positioning of a guidewire through the occlusion. However, hard occlusive material can be difficult or almost impossible to penetrate. Often, during such procedures, the guidewire deflects from the occlusion and penetrates into an extraluminal space (i.e., subintimal or outside the vessel). The guidewire may even perforate the vessel, resulting in the distal end of the guidewire positioned outside of the vessel wall. Such perforations are very dangerous in certain circulations (e.g., in the brain and the heart). But, perforations are less risky in peripheral arterial circulations and in most of the venous system due to the muscular tissue surrounding these areas. A guidewire positioned in the extraluminal space, between layers of the vessel or outside of the vessel, must be repositioned and/or directed into the central lumen of the vessel. However, redirecting the guidewire is often difficult or impossible, even with the use of ancillary deflecting catheters or devices.


SUMMARY OF THE INVENTION

The devices and methods of the present invention have several features, no single one of which is solely responsible for its desirable attributes. Without limiting the scope of this invention as expressed by the claims which follow, its more prominent features will now be discussed briefly. After considering this discussion, and particularly after reading the section entitled “Detailed Description of Certain Preferred Embodiments” one will understand how the features of this invention provide several advantages over traditional procedures relating to the treatment of vascular or venous occlusions.


One aspect is an ultrasonic reentry device that includes an elongate ultrasound transmission member that has a proximal end coupled to a sonic connector and a distal end configured to penetrate a vessel wall. The device further includes a catheter body that has a distal end and at least one lumen extending longitudinally therethrough. The lumen surrounds at least a portion of the ultrasound transmission member. The device further includes a dilator removably coupled to the catheter body and surrounding at least a portion of the ultrasound transmission member. The dilator has a length sized to expose at least a portion of the distal end of the ultrasound transmission member when the ultrasound transmission member is disposed within the dilator.


Another aspect is an ultrasonic device for entering and exiting an extraluminal space of a vessel. The device includes a catheter body that has at least one lumen extending longitudinally therethrough and an elongate ultrasound transmission member extending longitudinally through the lumen. At least a portion of the ultrasound transmission member has an outer surface that tapers to a needle-like distal end. The device further includes a dilator disposed over at least a portion of the ultrasound transmission member and configured to follow the ultrasound transmission member into the extraluminal space. At least a portion of the catheter body overlaps at least a portion of the dilator. The device further includes a sheath removably disposed over at least a portion of the dilator.


Another aspect is a method of re-entry from an extraluminal space into a central lumen of a vessel. The method includes positioning an ultrasonic device having a distal end in a first position within the central lumen of the vessel and penetrating the vessel with the distal end of the ultrasonic device. The method further includes advancing the distal end to a second position within the extraluminal space of the vessel and articulating at least a portion of the distal end of the ultrasonic device. The method further includes transmitting a vibration to the distal end of the ultrasonic device and advancing the distal end to a third position different from the first position within the central lumen.


Another aspect is a method of re-entering a central lumen of a vessel from an extraluminal space of the vessel. The method includes advancing a sheath over a guidewire positioned in the extraluminal space of the vessel, removing the guidewire, and advancing an ultrasonic device having a distal end through the sheath. The method further includes articulating at least a portion of the sheath towards the central lumen of the vessel, transmitting a vibration to the distal end of the ultrasonic device, and re-entering the central lumen of the vessel with the distal end of the ultrasonic device.


Another aspect is a system configured to re-enter from an extraluminal space into a central lumen of a vessel. The system can be configured to position an ultrasonic device having a distal end in a first position within the central lumen of the vessel and to penetrate the vessel with the distal end of the ultrasonic device. The system can be further configured to advance the distal end to a second position within the extraluminal space of the vessel and to articulate at least a portion of the distal end of the ultrasonic device. The system can be further configured to transmit a vibration to the distal end of the ultrasonic device and to advance the distal end to a third position different from the first position within the central lumen.


Another aspect is a system configured to re-enter a central lumen of a vessel from an extraluminal space of the vessel. The system can be configured to advance a sheath over a guidewire positioned in the extraluminal space of the vessel, to remove the guidewire, and to advance an ultrasonic device having a distal end through the sheath. The system can be further configured to articulate at least a portion of the sheath towards the central lumen of the vessel, transmit a vibration to the distal end of the ultrasonic device, and re-enter the central lumen of the vessel with the distal end of the ultrasonic device.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an ultrasound system that can be used for vascular re-entry according to a preferred embodiment of the present invention.



FIG. 2A is a side view of the ultrasound device shown in FIG. 1 coaxially located within a removable sheath.



FIG. 2B is a side view of the ultrasound device shown in FIG. 2A with the sheath removed.



FIG. 2C is a side view of the sheath from FIG. 2A showing an articulating distal end in dashed lines.



FIG. 3A is an enlarged side view of the ultrasound device as shown in FIG. 2B.



FIG. 3B is a cross-sectional view of the ultrasound device as shown in FIG. 3A.



FIG. 4A is an enlarged view of a portion of the ultrasound device about line 4A in FIG. 3B.



FIG. 4B is a view similar to FIG. 4A except the dilator is removed from the catheter body.



FIG. 5A is an enlarged view of an embodiment of a distal end of the ultrasound device about line 5 in FIG. 4A.



FIG. 5B is an enlarged view of another embodiment of the distal end of the ultrasound device about line 5 in FIG. 4A.



FIG. 6 shows a longitudinal cross-sectional view of an artery having a total occlusion (TO) or chronic total occlusion (CTO).



FIG. 6A shows a lateral cross-sectional view through the artery of FIG. 6 taken at line 6A-6A.



FIGS. 7-13 show an exemplary series of steps to bypass the CTO using the ultrasound device disclosed herein.



FIG. 14 is a flow diagram illustrating a method of bypassing the CTO by re-entering the artery from an extraluminal space.



FIGS. 15-25 show another exemplary series of steps to repair an unsuccessful bypass procedure by repositioning a conventional guidewire using the ultrasound device disclosed herein.





DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS

The following description and the accompanying figures describe and show the preferred embodiments as well as demonstrate several possible configurations for a re-entry device, system, and method. The illustrations are not intended to limit the disclosed aspects and features of the invention to the specified embodiments or to usage only with the illustrated device. Those of skill in the art will recognize that the disclosed aspects and features of the invention are not limited to any particular embodiment of a re-entry device, which may include one or more of the inventive aspects and features described herein.


To assist in the description of these components of the re-entry device, the following coordinate terms are used. A “longitudinal axis” is generally parallel to a portion of the re-entry device as well as parallel to the axis of a vessel through which the device can travel. A “lateral axis” is normal to the longitudinal axis. A “transverse axis” extends normal to both the longitudinal and lateral axes. In addition, as used herein, “the longitudinal direction” refers to a direction substantially parallel to the longitudinal axis; “the lateral direction” refers to a direction substantially parallel to the lateral axis; and “the transverse direction” refers to a direction substantially parallel to the transverse axis. The term “axial” as used herein refers to the axis of the re-entry device, and therefore is substantially synonymous with the term “longitudinal” as used herein. Also, the terms “proximal” and “distal,” which are used to describe the present system, are used consistently with the description of the exemplary applications (i.e., the illustrative examples of the use applications). Thus, proximal and distal are also used in reference to the respective ends of the re-entry device.


To facilitate a complete understanding of the embodiments, the remainder of the detailed description describes the re-entry system with reference to the Figures; wherein like elements among the embodiments are referenced with like numerals throughout the following description.



FIG. 1 shows an example of a perspective view of an ultrasound system 100 that can be used for vascular re-entry. The ultrasound system 100 includes an ultrasound device 120 which is releasably coupled to an ultrasound transducer 126. The ultrasound transducer 126 is electrically coupled to a signal generator 127.


The ultrasound device 120 may include an elongate body having a proximal portion 122 and a distal portion 121. The ultrasound device 120 may be an ultrasonic energy delivery member, or a catheter having at least one lumen extending longitudinally with an ultrasound transmission member extending therethrough.


The ultrasound device 120 may also include a Y-connector 123 that is operatively coupled to the ultrasound transducer 126. For example, the Y-connector 123 may be coupled to the ultrasound transducer 126 by way of a device knob 124 and a slide collar 125. The ultrasound transducer 126 may be connected to a signal generator 127, which may be coupled to a foot actuated on-off switch 128. The signal generator 127 can be supported by an IV pole 129. When the on-off switch 128 is depressed, the signal generator 127 can send an electrical signal to the ultrasound transducer 126, which converts the electrical signal to ultrasound energy. Such ultrasound energy can subsequently pass through the ultrasound device 120 and be delivered to the distal portion 121. A conventional guidewire (not shown) may be utilized in conjunction with the device 120.


The frontal portion of the Y-connector 123 may be connected to the proximal end 122 of the ultrasound device 120 using techniques that are well-known in the art. An injection pump 130 or IV bag (not shown) or syringe (not shown) may be connected, by way of an infusion tube 131, to an infusion port or sidearm 132 of the Y-connector 123. The injection pump 130 can be used to infuse coolant fluid into and/or through the device 120. Such flow of coolant fluid may be utilized to prevent overheating of the ultrasound transmission member and may serve to bathe the outer surface of the ultrasound transmission member, thereby providing for an equilibration of temperature between the coolant fluid and the ultrasound transmission member. The temperature and/or flow rate of coolant fluid may be adjusted to provide adequate cooling and/or other temperature control of the ultrasound transmission member. The irrigation fluid can include a pharmacological agent and/or microbubbles. In addition to the foregoing, the injection pump 130 or syringe may be utilized to infuse a radiographic contrast medium into the device 120 for purposes of imaging. Examples of iodinated radiographic contrast media which may be selectively infused into the ultrasonic device 120 via the injection pump 130 are commercially available as Angiovist 370 from Berlex Labs, Wayne, N.J. and Hexabrix from Malinkrodt, St. Louis, Mo.


Generally, the ultrasonic device 120 may include any suitable number of side-arms or ports for passage of a guidewire, application of suction, infusing and/or withdrawing irrigation fluid, dye and/or the like, or any other suitable ports or connections. Also, the device may be used with any suitable ultrasound transducer 126, signal generator 127, coupling device(s) and/or the like. Therefore, the exemplary embodiment shown in FIG. 1 and any following descriptions of proximal apparatus or systems for use with ultrasound devices 120 should not be interpreted to limit the scope of the present invention as defined in the appended claims.



FIG. 2A is a side view of the vascular re-entry device shown in FIG. 1 disposed within a removable sheath. The illustrated embodiment of the ultrasound device 120 includes an ultrasound transmission member 230, a dilator 206, and a sheath 240 which together form a tri-axial configuration.


As shown in FIG. 2A, the sheath 240 is removably coupled to the ultrasound device 120. The sheath 240 can be sized and shaped to fit over the catheter body 204, the dilator 206, and the ultrasound transmission member 230. The length of the sheath 240 may be selected such that a portion of the dilator 206 and/or a portion of the ultrasound transmission member 230 remain uncovered by the sheath 204 when the sheath 204 is coupled to the ultrasound device 120.



FIG. 2B is a side view of the ultrasound device 120 shown in FIG. 2A with the sheath 240 removed. As illustrated, the distal portion of the Y-connector 123 is coupled to a catheter body 204. The catheter body 204 can be coupled to the dilator 206. The ultrasound transmission member 230 can pass through the device knob 124, Y-connector 123, catheter body 204, dilator 206, and emerge at the distal end of the ultrasound device 120.


Turning to FIG. 2C, the sheath 240 can be removed from the ultrasound device 120. The sheath 240 may include a proximal handle 248, an actuating distal portion 242, and at least one lumen extending therethrough. The handle 248 may include a mechanism for actuating 246 the distal portion 242. The mechanism 246 may be a member 243 which slides within a channel 245. The member 243 may be coupled to a puller wire (not shown) such that when the member 243 is moved in a longitudinal direction away from the distal portion 242, the puller wire is moved in the same direction causing the distal portion 242 to deflect. In some embodiments, the distal portion 242 deflects up to about 90° from the longitudinal axis. In other embodiments, the distal portion 242 deflects greater than 90°. An advantage of an articulating distal portion 242 over a pre-shaped or curved catheter is the distal portion 242 remains straight when propagating though a vessel and/or extraluminal space, thus reducing trauma to the vessel. Furthermore, the actuating distal portion 242 may allow for added control and accuracy because the amount of deflection can be controlled and/or selected. Sheath 240 may be similar to commercially available sheaths such as, for example, the Bard® Channel™ Steerable Sheath (available from C.R. Bard, Inc., Lowell, Mass.), the CPS Venture® Wire Control Catheter (available from St. Jude Medical, Inc., St. Paul, Minn.), and the Morph® Vascular Access Catheter (available from BioCardia, Inc., San Carlos, Calif.) or other similar such products.


The handle 248 may be coupled with a shaft 241 having at least one lumen extending therethrough. In some embodiments, the shaft 241 is generally tubular in shape and may be constructed to resist snaking when pushed. A stiff shaft construction can prevent snaking when the puller wire is actuated causing the distal portion 242 to deflect. The sheath 240 may be any suitable length, for example, in the range of about 70-150 mm and any suitable diameter, for example, in the range of about 1.5-2.5 mm in order to be positioned though a vascular or venous system.


In some embodiments, the distal portion 242 includes one or more radiopaque markers 244. In one embodiment, the distal portion 242 is made of a radiopaque polymer or similar materials known in the art. The radiopaque materials can increase visibility under fluoroscopy and facilitate the correct positioning of the device. In another embodiment, intravascular ultrasound or other imaging modalities may be employed.


Alternate imaging techniques may include Optical Coherence Tomography (OCT) and/or magnetic fields (Stereotaxis Inc.) to further facilitate orientation of the distal portion 242 towards the central lumen of a vessel and further aid in the re-entry procedure.



FIG. 3A is an enlarged side view of the ultrasound device 120 as shown in FIG. 2B. In the illustrated embodiment, the device knob 124 includes a proximal housing 208. The housing 208 may include one or more surface features 212 for increasing the outer surface area of housing 208. Increased surface area can enhance the ability of housing 208 to dissipate heat generated by ultrasound transmission member 230. Surface features 212 may be of any suitable size or shape and can include, for example, ridges, jags, undulations, grooves or the like. Any suitable number of surface features 212 may be used. Additionally, the housing 208 may be made of one or more heat dissipating materials, such as aluminum, stainless steel, any other conductive metal(s), or any suitable non-metallic conductive material.


The catheter body 204 may be a generally flexible, tubular, elongate member, having any suitable diameter and length for reaching a vascular occlusion. Some embodiments, for example, the catheter body 204 has a length in the range of about 100200 cm. In one embodiment, the catheter body 204 has an outer diameter in the range of about 0.5-5.0 mm. In other embodiments, for use in relatively small vessels for example, the catheter body 204 may have an outer diameter in the range of about 0.25-2.5 mm. However, any other suitable length or diameter may be used without departing from the scope of the present invention. Examples of catheter bodies similar to those which may be used in the present invention are described in U.S. Pat. Nos. 5,267,954 and 5,989,208, which are herein incorporated by reference in their entireties. The catheter body 204 can insulate the ultrasound transmission member 230 and prevent an operator's hands from contacting the ultrasound transmission member 230 during use of the device.



FIG. 3B shows a cross-sectional view of the ultrasound device 120. As depicted, the housing 208 can include an inner cavity 244. Disposed within the cavity 244 is a sonic connector 252. The ultrasound transmission member 230 extends in a distal direction from the sonic connector 252 and through the cavity 244.


The inner cavity 244 may include one or more vibration absorption members 250. The vibration absorption members 250 can increase the ease of use by decreasing vibrations transmitted from the ultrasound transmission member 230 through the housing 208. The sonic connector 252 can facilitate the coupling of the ultrasound transmission member 230 to an ultrasound transducer device 126. The ultrasound transmission member 230 may extend distally from the sonic connector 252, through the inner cavity 244, Y-connector 216, catheter body 204, and dilator 206.


Continuing with FIG. 3B, the sidearm 132 may include a lumen 232 in fluid communication with a lumen 223 in the Y-connector 123. The lumen 223 in the Y-connector 123 can be in fluid communication with a lumen extending through the catheter body 204. Thus, fluid introduced into the sidearm 132 may flow into and through the catheter body 204 and contact the ultrasound transmission member 230. The fluid may flow out of the catheter body 204 through apertures in the distal portions (not shown) or through any other suitable apertures or openings, such as apertures located in the catheter body 204 itself.


Any suitable fluid may be passed through the sidearm 132 and catheter body 204. Suitable fluids include, for example, refrigerated fluids, lubricious fluids, super-saturated saline or contrast/saline mixtures, or the like. Cooling and/or lubricating the ultrasound transmission member 230 may reduce friction and/or wear and tear of the ultrasound transmission member 230, thus prolonging the ultrasound transmission member's useful life and enhancing overall performance.


In some embodiments, the ultrasound transmission member 230, wire, or wave guide extends longitudinally through a lumen of the catheter body 204. Ultrasonic energy can travel through the ultrasound transmission member 230 from an ultrasound transducer 126 connected to the proximal end of housing 208 to the distal portion of the device. The ultrasound transmission member 230 may operate at frequencies between about 10 Hz to about 20 MHz. In one embodiment, the frequency of vibration is 20 kHz. The ultrasound transmission member 230 may operate in continuous mode, pulse mode, or combination of both.


The ultrasound transmission member 230 may be formed of any material capable of effectively transmitting ultrasonic energy from the ultrasound transducer to the distal end of the ultrasound transmission member 230. These materials include, but are not limited to, metals such as pure titanium or aluminum, or titanium or aluminum alloys, such as NiTi. The ultrasound transmission member 230 may include one or more tapered regions and/or steps. The tapered regions and steps may increase and/or decrease in width or diameter along the length of the ultrasound transmission member 230 in the distal direction. In one embodiment, the ultrasound transmission member 230 includes at least one portion tapered in a direction extending distally from the proximal end. In another embodiment, the ultrasound transmission member 230 is continuously tapered in a direction extending distally from the proximal end. In one embodiment, the ultrasound transmission member 230 tapers in diameter from about 800 pm proximally, to about 200 pm distally.


Additional details of ultrasound systems and devices that include ultrasound transmission members (and their distal tips), ultra-sound transducers, sonic connectors and their connections to ultrasound devices are disclosed in U.S. Pat. Nos. 6,007,514, 6,427,118; 6,702,748; 6,855,123; 6,942,620; 6,942,677; 7,137,963; 7,220,233; 7,297,131; 7,335,180; 7,393,338; 7,540,852, 7,604,608 and in U.S. Pat. Pub. Nos. 2008/0108937, 2008/0287804, 2010/0317973, the disclosures of which are hereby incorporated by reference in their entireties.


Continuing with FIG. 3B, the Y-connector 123 can be coupled to the catheter body 204. The catheter body 204 can be coupled to the removable dilator 206. The Y-connector 123 can be coupled to the catheter body 204 by any coupling manner well known in the art and in some embodiments is fixably attached. Similarly, the removable dilator 206 can be coupled to the catheter body 204 in any manner well known in the art. In some embodiments, a separate coupling structure is used.


In some embodiments, as shown for example in FIGS. 4A and 4B, the removable dilator 206 is coupled to the catheter body 204 such that the catheter body 204 overlaps at least a portion of the dilator 206. As illustrated, a proximal portion of the dilator 206 is sized to fit within a distal portion of the catheter body 204. In other words, the dilator 206 can be placed around the ultrasound transmission member 230 and fit within the catheter body 208.


In some embodiments, an outer surface of the dilator 206 contacts an inner surface of the catheter body 204. Friction between the two surfaces can secure the dilator 206 in place. The length of the dilator 206 may be selected so that at least a portion of the ultrasound transmission member 230 is exposed at the distal end. The total length of the dilator 206 can be selected, for example, such that about 5 mm of the distal portion of the ultrasound transmission member 230 is exposed when a proximal portion of the dilator 206 is fit snugly within the distal portion of the catheter body 204.


The dilator 206 may be a thin walled tubular member and constructed such that the dilator 206 is resistant to bending or kinking when pushed. The dilator 206 may be formed with any suitable material well known in the art, including but not limited to flat-ribbon braided polyamide, or may comprise a hypotube catheter shaft of stainless steel, titanium, NiTi, or similar metal/alloy. In one embodiment, at least a portion of the dilator 206 is tapered in a direction extending distally from the proximal end. In another embodiment, the dilator 206 is continuously tapered in a direction extending distally from the proximal end.


Turning to FIG. 4B, a distal portion of the dilator 206 may have a similar profile to the ultrasound transmission member 230 such that the distal portion of the dilator 206 is sized to facilitate the following of the ultrasound transmission member 230 into the extraluminal space. In use, the dilator 206 can serve as a transition member between the relatively small diameter of the ultrasound transmission member 230 and the relatively larger diameter of the sheath 240. For example, the dilator 206 can follow the ultrasound transmission member 230 into the extraluminal space and the sheath 240 can then follow the dilator 206 into the extraluminal space as well. In one embodiment, the distal portion of the dilator 206 has an inner diameter di and outer diameter do in the range of about 500-250 pm. In one embodiment, the inner diameter d, is about 380 pm and the outer diameter do is about 480 pm.



FIGS. 5A and 5B show enlarged side views of exemplary embodiments of the distal tip 239 of the ultrasound transmission member 230. In some embodiments, the distal tip 239 is integral to the ultrasound transmission member 230 and is not formed by a separate tip structure or component attached to the ultrasound transmission member 230. Rather, in these embodiments, the distal tip 239 is formed by shaping the distal end of the ultrasound transmission member 230. A sharpened distal end facilitates penetration into blood vessel materials. The lack of an affixed tip structure which often includes a larger diameter allows for greater power intensity to be transmitted to the distal tip 239 of ultrasound transmission member 230. FIG. 5A shows a distal tip 239a with a chiseled end, having a beveled edge 233. FIG. 5A shows a distal tip 239b with a rounded edge 235. Other similar constructions may also be implemented. For example, in one embodiment, the distal tip of ultrasound transmission member 239 has a conical shape.


A Total Occlusion (“TO”) can be defined as an artery or vein that has been completely occluded. An acute TO is usually associated with a sudden blockage, resulting in no blood flow to and from surrounding tissue, and is potentially life threatening. In contrast, Chronic Total Occlusions (“CTO”) are blockages that have formed for at least thirty days and are less life-threatening. In such cases, the areas around the CTO tend to develop collateral blood supply.



FIG. 6 illustrates a longitudinal cross-sectional view of an artery 600 having a total occlusion 650. The total occlusion 650 usually consists of atheroma, thrombus, plaque, calcific material, or combinations of thereof. For illustrative purposes, an arterial CTO 650 is shown in connection with the device and method described with respect to FIGS. 7-13. However, all the devices and methods described herein can also apply to CTOs within veins. Further, although the ultrasonic device will be shown and described for use in and about an artery, the device may also be used in other blood vessels including veins and capillaries or in other tubular channels, for example channels of the lymphatic system. As illustrated in FIG. 6, the arterial occlusion 650 occupies the entire diameter of the lumen, thus blocking blood flow. It is desirable to open such an occlusion, restoring blood flow through affected areas, and thus improving blood supply and heart function.



FIG. 6A illustrates a cross section of the artery 600 about the line 6A-6A as viewed in a direction distal to the occlusion. The artery has a central lumen 601 and arterial wall with three layers: intima 602, intermedia 603 and adventitia 604. All three layers consist of elastic tissue, smooth muscle and connecting tissue (collagen). The tissue of the arterial wall is often called a subintimal space. The area outside the adventitia 604, an external layer of the artery, is called a space outside of the vessel. Both areas, subintimal space and outside the vessel space, are referred to collectively herein as “extraluminal space.”



FIGS. 7-13 illustrate the steps of an exemplary use of the ultrasonic device 120 in a vascular re-entry procedure. As shown in FIG. 7 the ultrasonic device 120 can be positioned in the vessel 600 and advanced until the device 120 encounters the occlusion 650. In the illustrated embodiment, the ultrasonic device 120 includes an ultrasound transmission member 230 disposed within a dilator 206. The dilator 206 and ultrasound transmission member 230 are further disposed within the sheath 240. The sheath 240 includes an articulating distal portion.


Sometimes, the ultrasonic device 120 can be successfully advanced through the occlusion 650 and positioned in the central lumen 601d of the vessel 600, distal to the occlusion. However, as shown in FIG. 8, the ultrasonic device 120 may deflect away from the occlusion 650 and toward the wall of the vessel. In FIG. 8, the ultrasonic device 120 is shown as deflecting laterally, towards the vessel wall.


With reference to FIG. 9, the ultrasonic device 120 is advanced further so as to penetrate the intima layer 602 of the vessel 600. A sharp tipped 239 ultrasound transmission member 230 can allow for easier penetration into the intima layer 602. As the ultrasonic device 120 is advanced further, the low-profile dilator 206 follows the ultrasound transmission member 230 into the intima layer 602 as well.


Continuing to FIG. 10, the ultrasonic device 120 is advanced further within the extraluminal space of the vessel 600. As illustrated, the sheath 240 follows the dilator 206 into the intima layer 602 such that the distal portion of the ultrasonic device 120 is positioned between the intima layer 602 and the intermedia layer 603. The ultrasonic device 120 may also be advanced into the adventitia 604 layer or even to areas outside the vessel 600. In one embodiment, the ultrasonic device 120 is advanced within the subintimal space until it passes the occlusion 650.


Vessel trauma can be minimized if the distance that the ultrasonic device 120 travels through the subintimal space is minimized. Thus, it is desirable that the path length of the ultrasonic device 120 through the subintimal space is as short as possible. In some embodiments, the ultrasonic device 120 is advanced to just beyond the proximal end of the occlusion 650. Often, when occlusions are long and there is evidence of softer occlusion composition, the proximal advancement of the ultrasonic device 120 should be limited as much as possible. Thus, if possible, re-entry within the occlusion 650 should be considered as well to minimize the length of the subintimal space in which the ultrasonic device 120 will occupy.


With other similar devices, re-entry from the subintimal or extraluminal space into the central distal lumen 601d may be difficult. For example, a conventional guidewire may be unable to re-enter into the distal central lumen 601d due to the muscular vessel structure which may prevent the relative soft guidewire from puncturing the vessel wall. A directing catheter disposed over the guidewire may also not provide sufficient support for the guidewire to puncture the vessel wall. Traditional directing catheters are often pre-shaped, causing added damage to the vessel wall.



FIG. 11 shows a distal portion of the ultrasonic device 120 positioned within the subintimal space beyond the occlusion 650. In one embodiment, the position of the sheath 240 is determined at least in part by visualizing the radiopaque markers 244 with fluoroscopy techniques. The ultrasonic device 120 can be rotated and/or advanced as desired based at least in part on the known location of the radiopaque markers 244. Once the ultrasonic device 120 is placed in a desired position, the sheath 240 can be actuated such that the distal portion of the sheath 240 deflects in a direction towards the distal central lumen 601d. The precise amount of deflection can be selected and/or varied during the procedure by the device operator.


In order to determine the precise position and orientation of the ultrasonic device 120, extensive flouroscopical visualization from several X-ray machine angles may be required. Such visualization may be needed during positioning to assure that the distal portion of the device is directed towards the distal central lumen 601d. Use of endovascular ultrasound or other visualization devices, either in arteries or in adjacent veins, may also facilitate directing the distal portion of the ultrasonic device 120 towards the distal central lumen 601d.


According to one embodiment, when it is confirmed that the distal portion of the ultrasonic device 120 is directed towards the distal central lumen 601d, ultrasonic energy is transmitted to the distal portion of the ultrasound transmission member 230. The ultrasonic device 120 is then slowly advanced through the subintimal space to puncture the vessel wall. The ultrasonic device 120 can then be advanced into the distal central lumen 601d. The delivery of ultrasonic energy may then be reduced or stopped.


Ultrasonic energy, with its cavitational and/or thermal effects, may be helpful in ablating or penetrating, perforating, or piercing the vessel 600 and facilitate reentry into the distal central lumen 601d. Vibrational devices with longitudinal or transverse vibrational forces, rotational devices, or other heat generating devices such as radio frequency or microwave devices may be used to facilitate re-entry into the distal central lumen 601d. As such, in other embodiments, the ultrasonic device 120 may include other vibrational devices, rotational devices, cutting devices, radio frequency devices, laser devices, microwave devices, puncture devices, and the like.



FIG. 12 illustrates a distal portion of the ultrasonic device 120 positioned in the distal central lumen 601d beyond the occlusion 650. In some embodiments, the portion of the ultrasound transmission member 230 exposed (i.e. not covered by the dilator 240 and/or sheath 206) is minimized in order to reduce the potential for piercing the opposite wall of the vessel 600.


In the embodiment shown in FIG. 13, once at least a portion of the sheath 240 is positioned distal to the occlusion 650 and within the distal central lumen 601d, the ultrasound transmission member 230 and the dilator 206 can be removed from the sheath 240. An adjunctive angioplasty such as balloon angioplasty and/or stenting can then be inserted into the sheath 240. The sheath 240 can then be removed and the adjunctive angioplasty can be deployed, completing the procedure according to one embodiment.



FIG. 14 is a flow diagram illustrating a method of re-entry from an extraluminal space into a lumen of a vessel. The method 1400 begins at block 1410 by positioning an ultrasound device 120 in a first position within a lumen of a vessel. The first position may be proximal to a vessel blockage. The method continues at block 1420 by penetrating the vessel wall with a distal end of the ultrasound device 120. At least a portion of the distal end preferably articulates or bends. In some embodiments, the ultrasound transmission member includes a sharpened distal end configured to facilitate the ultrasound device 120 penetrating the vessel wall. The method continues at block 1430 by advancing the distal end of the ultrasound device to a second position. The second position may be within an extraluminal space of the vessel, for example, in a space outside of the lumen of the vessel, or within the vessel wall. In some embodiments, at least a portion of the distal end is articulated to bend in a direction towards or away from the vessel wall.


The method 1400 continues at block 1440 by transmitting a vibration to the distal end. The vibration may be in the form of an ultrasonic vibration transmitted from a proximal end of the ultrasonic device to the distal end. The method 1400 can end at block 1450 by advancing the distal end to a third position different from the first position within the lumen. The third position may be at a position distal to the vessel blockage. The ultrasound device 120 may include an outer lumen surrounding an ultrasound transmission member 230. In some embodiments the method continues by removing the ultrasound transmission member 230 from the lumen and replacing it with a scent or balloon catheter or the like.



FIGS. 15-25 show another exemplary series of steps to repair an initially unsuccessful bypass procedure using the ultrasound device 120 disclosed herein. As discussed above, an occluded vessel can be treated at least in part by positioning a guidewire through the occlusion. For some methods of bypassing an occlusion or CTO, the procedure initially begins with the medical provider feeding a conventional guidewire through the vasculature and adjacent to the CTO. The medical provider may then press the guidewire firmly against the CTO in an attempt to penetrate the CTO unaided by the ultrasound device 120. In such cases, the guidewire may successfully penetrate the CTO or be deflected away from the CTO and into the wall of the vessel. In some cases the deflected guidewire punctures the vessel wall and enters the subintimal space. As set forth below, one of the many medical uses for the ultrasound device 120 is to reposition such a guidewire back within the true lumen of the vessel.



FIG. 15 illustrates a traditional guidewire 800 that has deflected away from an occlusion 650, toward the wall of the vessel, and into the subintimal space. The tri-axial ultrasound device 120 can be used in a method to reposition the guidewire 800 in a desired position as described below.


In some embodiments, the bailout method begins as is illustrated in FIG. 16 with a sheath 240 being advanced over the guidewire 800 and into the subintimal space of the vessel. The sheath 240 may include radiopaque markers 244 to help determine the precise position and orientation of the sheath 240. The sheath 240 can include an articulating distal end as discussed above.


The method continues in FIG. 17 by removing the guidewire 800 from the sheath after the sheath 240 has been advanced over the guidewire 800. In this way, at least a portion of the sheath 240 remains at least partially within the subintimal space. The positioning of the sheath 240 can be determined, for example, by visualizing the radiopaque markers 244.


The articulating distal end of the sheath 240 can then be actuated such that a distal portion of the sheath 240 deflects in a direction toward the distal central lumen 601d of the vessel as shown in FIG. 18. FIG. 18 illustrates an embodiment in which the sheath 240 is articulated with the guidewire 800 removed. However, the sheath 240 can be articulated before the guidewire 800 is removed as well. The sheath 240 can also be articulated before or after other devices or lumens have been inserted into the sheath 240.


The next step of the method is illustrated in FIG. 19. An ultrasound transmission member 230 is advanced through the sheath 240. The ultrasound transmission member 230 may include a distal tip configured to penetrate tissue. The ultrasound transmission member 230 may be connected to a source of ultrasonic energy and configured such that ultrasonic vibrations can be transmitted to the tip of the ultrasound transmission member 230 to facilitate penetration of the vessel wall and/or to assist in re-entry from the subintimal space and into the distal central lumen 601d. As shown in FIG. 19, a distal portion of the ultrasound transmission member 230 has entered the distal central lumen 601d from the subintimal space.


Turning to FIG. 20, the method continues by advancing the dilator 206 over the ultrasound transmission member 230, through the sheath 240, and into the distal central lumen 601d. The dilator 206 may have a distal portion having a similar profile to the ultrasound transmission member 230 such that the distal portion of the dilator 206 can facilitate the following of the ultrasound transmission member 230 from the extraluminal or subintimal space and into the central lumen 601. In this way, the dilator 206 serves as a transition member between the relatively small diameter of the ultrasound transmission member 230 and the relatively larger diameter of the sheath 240. In some embodiments, at least a portion of the dilator 206 is tapered in a direction towards the distal tip of the dilator 206.


In one embodiment, the dilator 206 is inserted into the sheath 240 before the ultrasound transmission member 230 is inserted. That is to say, after the guidewire 800 is removed from the sheath 240, the dilator 206 is advanced through the sheath 240. Next, the ultrasound transmission member 230 is advanced through the dilator 206. The ultrasound transmission member 230 can then be advanced through the extraluminal space so as to re-enter the distal central lumen 601d through the vessel wall.


In some embodiments, the dilator 206 and ultrasound transmission member 230 are sized such that the ultrasound transmission member 230 only advances outside the distal end of the dilator 206 by a maximum distance (for example, about 5 mm or less). For example, the ultrasound transmission member 203 and the dilator 206 can be sized and/or tapered in such a way that the ultrasound transmission member 203 extends beyond the end of the dilator 206 a predetermined amount before the walls of the dilator 206 prevent further advancement of the ultrasound transmission member 230. In this way, the dilator 206 can serve to prevent the ultrasound transmission member 230 from being advanced too far distally, thus minimizing the potential of the ultrasound transmission member 230 piercing the opposite vessel wall.


Turning to FIG. 21, the ultrasound transmission member 203 can be removed after the dilator 206 is positioned in the distal central lumen 601d. Next, as shown in FIG. 22, the guidewire 800 can be advanced through the dilator 206 and into the distal central lumen 601d. The sheath 240 and dilator 206 can then be removed as shown in FIG. 23 leaving the distal end of the guidewire 800 in the distal central lumen 601d. The sheath 240 and/or 206 dilator can be removed together or separately in any order.


As shown in FIG. 24, once the guidewire 800 has crossed over the occlusion 650, a balloon catheter 805 with a stent 801 can be advanced over the guidewire 800 and positioned within the region of the occlusion 650. The balloon catheter 805 can then be expanded deploying the stent 801. The balloon catheter 805 and guidewire 800 can then be removed, leaving the fully deployed stent 805 in the vessel as shown in FIG. 25.


The various embodiments described above thus provide a number of ways to provide for treatment of occluded vessels. In addition, the techniques described may be broadly applied for use with a variety of medical procedures. Of course, it is to be understood that not necessarily all such objectives or advantages may be achieved in accordance with any particular embodiment using the systems described herein. Thus, for example, those skilled in the art will recognize that the systems may be developed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.


Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments. Although these techniques and devices have been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that these techniques and devices may be extended beyond the specifically disclosed embodiments to other embodiments and/or uses and obvious modifications and equivalents thereof. Additionally, it is contemplated that various aspects and features of the invention described can be practiced separately, combined together, or substituted for one another, and that a variety of combination and subcombinations of the features and aspects can be made and still fall within the scope of the invention. Thus, it is intended that the scope of the systems disclosed herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.

Claims
  • 1. A method for operating an ultrasonic reentry device, comprising: providing an ultrasound transmission member having a proximal end and a distal end;providing a catheter body having a lumen surrounding the ultrasound transmission member;providing a dilator slidably disposed within the lumen of the catheter body, the dilator surrounding the ultrasound transmission member;exposing the distal end of the ultrasound transmission member from a distal end of the dilator; andproviding a sheath disposed over the dilator, the catheter body, and the ultrasound transmission member.
  • 2. The method of claim 1, wherein exposing the distal end protrudes the ultrasound transmission member 1-5 mm past the distal end of the dilator.
  • 3. The method of claim 1, comprising: exposing a distal end of the dilator from a distal end of the sheath.
  • 4. The method of claim 1, comprising: articulating a distal end of the sheath.
  • 5. The method of claim 4, wherein the act of articulating comprises articulating the distal end of the sheath up to 90 degrees away from a longitudinal axis.
  • 6. The method of claim 4, comprising: exposing the dilator and the ultrasound transmission member from the distal end of the sheath;articulating the distal end of the sheath in a first lateral direction;advancing a relative position of the combination of the sheath, the dilator, and the ultrasound transmission member;articulating the distal end of the sheath in a second lateral direction different from the first lateral direction; andfurther advancing the relative position of the combination of the sheath, the dilator, and the ultrasound transmission member.
  • 7. The method of claim 6, comprising transmitting an ultrasonic vibration to the distal end of the ultrasound transmission member prior to at least one of the advancing step and the further advancing step.
  • 8. The method of claim 6, comprising visualizing a distal portion of the sheath using fluoroscopy during each of the articulating and advancing steps.
  • 9. The method of claim 6, comprising removing the ultrasound transmission member and the dilator from the sheath following the step of further advancing.
  • 10. The method of claim 6, comprising: removing the ultrasound transmission member from the dilator following the step of further advancing; andinserting a guidewire through the dilator.
  • 11. A method for operating an ultrasonic reentry device, comprising: providing a catheter body having a lumen;providing an ultrasound transmission member disposed in the lumen, the ultrasound transmission member having a taper to a needle-like distal end;disposing a dilator over the ultrasound transmission member, with the catheter body overlapping the dilator;providing a sheath disposed over the dilator, the catheter body, and the ultrasound transmission member; andarticulating a distal end of the sheath to position the distal end of the ultrasound transmission member and a distal end of the dilator.
  • 12. The method of claim 11, wherein the act of articulating comprises articulating the distal end of the sheath up to 90 degrees away from a longitudinal axis.
  • 13. The method of claim 11, comprising exposing a distal end of the dilator from the distal end of the sheath.
  • 14. The method of claim 13, comprising exposing the distal end of the ultrasound transmission member from the distal end of the dilator.
  • 15. The method of claim 14, wherein exposing the distal end protrudes the ultrasound transmission member 1-5 mm past the distal end of the dilator.
  • 16. The method of claim 11, comprising: exposing the dilator and the ultrasound transmission member from the distal end of the sheath;articulating the distal end of the sheath in a first lateral direction;advancing a relative position of the combination of the sheath, dilator, and the ultrasound transmission member;articulating the distal end of the sheath in a second lateral direction different from the first lateral direction;transmitting an ultrasonic vibration to the distal end of the ultrasound transmission member; andfurther advancing the relative position of the combination of the sheath, the dilator, and the ultrasound transmission member.
  • 17. The method of claim 16, comprising transmitting an ultrasonic vibration to the distal end of the ultrasound transmission member prior to the first step of advancing.
  • 18. The method of claim 16, comprising visualizing a distal portion of the sheath using fluoroscopy during each of the articulating and advancing steps.
  • 19. The method of claim 16, comprising removing the ultrasound transmission member and the dilator from the sheath following the step of further advancing.
  • 20. The method of claim 16, comprising: removing the ultrasound transmission member from the dilator following the step of further advancing; andinserting a guidewire through the dilator.
PRIORITY

This application is a continuation of U.S. patent application Ser. No. 15/413,259, filed Jan. 23, 2017, now U.S. Pat. No. 10,357,263, which is a continuation of U.S. patent application Ser. No. 14/365,016, filed Oct. 8, 2014, now U.S. Pat. No. 9,603,615, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/US2012/021766, filed Jan. 18, 2012, each of which is incorporated by reference in its entirety into this application.

US Referenced Citations (458)
Number Name Date Kind
3296620 Rodda Jan 1967 A
3433226 Boyd Mar 1969 A
3443226 Knight May 1969 A
3565062 Kurls Feb 1971 A
3585082 Siller Jun 1971 A
3612038 Halligan Oct 1971 A
3631848 Muller Jan 1972 A
3679378 Van Impe et al. Jul 1972 A
3719737 Vaillancourt et al. Mar 1973 A
3739460 Addis et al. Jun 1973 A
3754746 Thiele Aug 1973 A
3823717 Pohlman et al. Jul 1974 A
3835690 Leonhardt et al. Sep 1974 A
3839841 Amplatz Oct 1974 A
3896811 Storz Jul 1975 A
4016882 Broadwin et al. Apr 1977 A
4033331 Guss et al. Jul 1977 A
4136700 Broadwin et al. Jan 1979 A
4337090 Harrison Jun 1982 A
4368410 Hance et al. Jan 1983 A
4417578 Banko Nov 1983 A
4425115 Wuchinich Jan 1984 A
4449532 Storz May 1984 A
4486680 Bonnet et al. Dec 1984 A
4505767 Quin Mar 1985 A
4535759 Polk et al. Aug 1985 A
4545767 Suzuki et al. Oct 1985 A
4565589 Harrison Jan 1986 A
4565787 Bossle et al. Jan 1986 A
4572184 Stohl et al. Feb 1986 A
4664112 Kensey et al. May 1987 A
4665906 Jervis May 1987 A
4679558 Kensey et al. Jul 1987 A
4700705 Kensey et al. Oct 1987 A
4721117 Mar et al. Jan 1988 A
4750902 Wuchinich et al. Jun 1988 A
4781186 Simpson et al. Nov 1988 A
4808153 Parisi Feb 1989 A
4811743 Stevens Mar 1989 A
4827911 Broadwin et al. May 1989 A
4838853 Parisi Jun 1989 A
4854325 Stevens Aug 1989 A
4870953 DonMicheal et al. Oct 1989 A
4886060 Wiksell Dec 1989 A
4920954 Alliger et al. May 1990 A
4923462 Stevens May 1990 A
4924863 Sterzer May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936845 Stevens Jun 1990 A
4979952 Kubota et al. Dec 1990 A
5000185 Yock Mar 1991 A
5015227 Broadwin et al. May 1991 A
5026384 Farr et al. Jun 1991 A
5030201 Palestrant Jul 1991 A
5030357 Lowe Jul 1991 A
5046503 Schneiderman Sep 1991 A
5053008 Bajaj Oct 1991 A
5058570 Idemoto et al. Oct 1991 A
5076276 Sakurai et al. Dec 1991 A
5091205 Fan Feb 1992 A
5100423 Fearnot Mar 1992 A
5109859 Jenkins May 1992 A
5114414 Buchbinder May 1992 A
5116350 Stevens May 1992 A
5127917 Niederhauser et al. Jul 1992 A
5131393 Ishiguro et al. Jul 1992 A
5156143 Bocquet et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5171216 Dasse et al. Dec 1992 A
5180363 Idemoto et al. Jan 1993 A
5183470 Wettermann Feb 1993 A
5195955 Michael Mar 1993 A
5215614 Wijkamp et al. Jun 1993 A
5217565 Kou et al. Jun 1993 A
5221255 Mahurkar et al. Jun 1993 A
5226421 Frisbie et al. Jul 1993 A
5234416 Macaulay et al. Aug 1993 A
5236414 Takasu Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5242385 Strukel Sep 1993 A
5243997 Uflacker et al. Sep 1993 A
5248296 Alliger Sep 1993 A
5255669 Kubota et al. Oct 1993 A
5267954 Nita Dec 1993 A
5269291 Carter Dec 1993 A
5269297 Weng et al. Dec 1993 A
5269793 Simpson Dec 1993 A
5287858 Hammerslag et al. Feb 1994 A
5290229 Paskar Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5304131 Paskar Apr 1994 A
5312328 Nita et al. May 1994 A
5318014 Carter Jun 1994 A
5318570 Hood et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324260 O'Neill et al. Jun 1994 A
5325860 Seward et al. Jul 1994 A
5326342 Pflueger et al. Jul 1994 A
5328004 Fannin et al. Jul 1994 A
5329927 Gardineer et al. Jul 1994 A
5341818 Abrams et al. Aug 1994 A
5342292 Nita et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5346502 Estabrook et al. Sep 1994 A
5362309 Carter Nov 1994 A
5368557 Nita Nov 1994 A
5368558 Nita et al. Nov 1994 A
5376084 Bacich et al. Dec 1994 A
5378234 Hammerslag et al. Jan 1995 A
5380274 Nita Jan 1995 A
5380316 Aita et al. Jan 1995 A
5382228 Nita et al. Jan 1995 A
5383460 Jang et al. Jan 1995 A
5389096 Aita et al. Feb 1995 A
5391144 Sakurai et al. Feb 1995 A
5397293 Alliger et al. Mar 1995 A
5397301 Pflueger et al. Mar 1995 A
5403324 Ciervo et al. Apr 1995 A
5405318 Nita Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5417672 Nita et al. May 1995 A
5417703 Brown et al. May 1995 A
5421923 Clarke et al. Jun 1995 A
5427118 Nita et al. Jun 1995 A
5431168 Webster, Jr. Jul 1995 A
5431663 Carter Jul 1995 A
5443078 Uflacker Aug 1995 A
5447509 Mills et al. Sep 1995 A
5449369 Imran Sep 1995 A
5449370 Vaitekunas Sep 1995 A
5451209 Ainsworth et al. Sep 1995 A
5462529 Simpson et al. Oct 1995 A
5465733 Hinohara et al. Nov 1995 A
5474530 Passafaro et al. Dec 1995 A
5474531 Carter Dec 1995 A
5480379 La Rosa Jan 1996 A
5484398 Stoddard Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5498236 Dubrul et al. Mar 1996 A
5507738 Ciervo Apr 1996 A
5516043 Manna et al. May 1996 A
5527273 Manna et al. Jun 1996 A
5540656 Pflueger et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5597497 Dean et al. Jan 1997 A
5597882 Schiller et al. Jan 1997 A
5607421 Jeevanandam et al. Mar 1997 A
5611807 O'Boyle Mar 1997 A
5618266 Liprie Apr 1997 A
5626593 Imran May 1997 A
5627365 Chiba et al. May 1997 A
5649935 Kremer et al. Jul 1997 A
5658282 Daw et al. Aug 1997 A
5665062 Houser Sep 1997 A
5685841 Mackool Nov 1997 A
5695460 Siegel et al. Dec 1997 A
5695507 Auth et al. Dec 1997 A
5715825 Crowley Feb 1998 A
5720724 Ressemann et al. Feb 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5738100 Yagami et al. Apr 1998 A
5797876 Spears et al. Aug 1998 A
5816923 Milo et al. Oct 1998 A
5827203 Nita Oct 1998 A
5827971 Hale et al. Oct 1998 A
5830127 DeCastro Nov 1998 A
5830222 Makower Nov 1998 A
5846218 Brisken et al. Dec 1998 A
5893838 Daoud et al. Apr 1999 A
5895397 Jang et al. Apr 1999 A
5902287 Martin May 1999 A
5904667 Falwell May 1999 A
5916192 Nita et al. Jun 1999 A
5916912 Ames et al. Jun 1999 A
5935142 Hood Aug 1999 A
5935144 Estabrook Aug 1999 A
5937301 Gardner et al. Aug 1999 A
5944737 Tsonton et al. Aug 1999 A
5957882 Nita et al. Sep 1999 A
5957899 Spears et al. Sep 1999 A
5964223 Baran Oct 1999 A
5967984 Chu et al. Oct 1999 A
5971949 Levin et al. Oct 1999 A
5976119 Spears et al. Nov 1999 A
5989208 Nita Nov 1999 A
5989275 Estabrook et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
6004280 Buck et al. Dec 1999 A
6004335 Vaitekunas et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6007514 Nita Dec 1999 A
6022309 Celliers et al. Feb 2000 A
6024764 Schroeppel Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6030357 Daoud et al. Feb 2000 A
6036689 Tu et al. Mar 2000 A
6051010 DiMatteo et al. Apr 2000 A
6066135 Honda May 2000 A
6113558 Rosenschein et al. Sep 2000 A
6120515 Rogers et al. Sep 2000 A
6123698 Spears et al. Sep 2000 A
6142971 Daoud et al. Nov 2000 A
6149596 Bancroft Nov 2000 A
6159176 Broadwin et al. Dec 2000 A
6165127 Crowley Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6179809 Khairkhahan et al. Jan 2001 B1
6180059 Divino, Jr. et al. Jan 2001 B1
6190353 Makower et al. Feb 2001 B1
6206842 Tu et al. Mar 2001 B1
6210356 Anderson et al. Apr 2001 B1
6217543 Anis et al. Apr 2001 B1
6217565 Cohen Apr 2001 B1
6217588 Jerger et al. Apr 2001 B1
6221015 Yock Apr 2001 B1
6231546 Milo et al. May 2001 B1
6231587 Makower May 2001 B1
6235007 Divino, Jr. et al. May 2001 B1
6241692 Tu et al. Jun 2001 B1
6241703 Levin et al. Jun 2001 B1
6248087 Spears et al. Jun 2001 B1
6277084 Abele et al. Aug 2001 B1
6283983 Makower et al. Sep 2001 B1
6287271 Dubrul et al. Sep 2001 B1
6287285 Michal et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6296620 Gesswein et al. Oct 2001 B1
6298620 Hatzinikolas Oct 2001 B1
6302875 Makower et al. Oct 2001 B1
6309358 Okubo Oct 2001 B1
6315741 Martin et al. Nov 2001 B1
6315754 Daoud et al. Nov 2001 B1
6331171 Cohen Dec 2001 B1
6346192 Buhr et al. Feb 2002 B2
6379378 Werneth et al. Apr 2002 B1
6387109 Davison et al. May 2002 B1
6387324 Patterson et al. May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6398736 Seward Jun 2002 B1
6409673 Yock Jun 2002 B2
6416533 Gobin et al. Jul 2002 B1
6423026 Gesswein et al. Jul 2002 B1
6427118 Suzuki Jul 2002 B1
6433464 Jones Aug 2002 B2
6434418 Neal et al. Aug 2002 B1
6450975 Brennan et al. Sep 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454997 Divino, Jr. et al. Sep 2002 B1
6484052 Visuri et al. Nov 2002 B1
6491707 Makower et al. Dec 2002 B2
6494891 Cornish et al. Dec 2002 B1
6494894 Mirarchi Dec 2002 B2
6500141 Irion et al. Dec 2002 B1
6508781 Brennan et al. Jan 2003 B1
6508784 Shu Jan 2003 B1
6511458 Milo et al. Jan 2003 B2
6514249 Maguire et al. Feb 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6533766 Patterson et al. Mar 2003 B1
6544215 Bencini et al. Apr 2003 B1
6547754 Evans et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6551337 Rabiner et al. Apr 2003 B1
6554846 Hamilton et al. Apr 2003 B2
6555059 Myrick et al. Apr 2003 B1
6558502 Divino, Jr. et al. May 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6573470 Brown et al. Jun 2003 B1
6576807 Brunelot et al. Jun 2003 B1
6582387 Derek et al. Jun 2003 B2
6589253 Cornish et al. Jul 2003 B1
6595989 Schaer Jul 2003 B1
6596235 Divino, Jr. et al. Jul 2003 B2
6602467 Divino, Jr. et al. Aug 2003 B1
6602468 Patterson et al. Aug 2003 B2
6605217 Buhr et al. Aug 2003 B2
6607698 Spears et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6613280 Myrick et al. Sep 2003 B2
6615062 Ryan et al. Sep 2003 B2
6616617 Ferrera et al. Sep 2003 B1
6622542 Derek et al. Sep 2003 B2
6623448 Slater Sep 2003 B2
6635017 Moehring et al. Oct 2003 B1
6650923 Lesh et al. Nov 2003 B1
6652547 Rabiner et al. Nov 2003 B2
6660013 Rabiner et al. Dec 2003 B2
6676900 Divino, Jr. et al. Jan 2004 B1
6682502 Bond et al. Jan 2004 B2
6685657 Jones Feb 2004 B2
6689086 Nita et al. Feb 2004 B1
6695781 Rabiner et al. Feb 2004 B2
6695782 Ranucci et al. Feb 2004 B2
6695810 Peacock, III et al. Feb 2004 B2
6702748 Nita et al. Mar 2004 B1
6702750 Yock Mar 2004 B2
6719715 Newman et al. Apr 2004 B2
6719725 Milo et al. Apr 2004 B2
6729334 Baran May 2004 B1
6733451 Rabiner et al. May 2004 B2
6758846 Goble et al. Jul 2004 B2
6761698 Shibata et al. Jul 2004 B2
6855123 Nita Feb 2005 B2
6866670 Rabiner et al. Mar 2005 B2
6936025 Evans et al. Aug 2005 B1
6936056 Nash et al. Aug 2005 B2
6942620 Nita et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6955680 Satou et al. Oct 2005 B2
7004173 Sparks et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7056294 Khairkhahan et al. Jun 2006 B2
7131983 Murakami Nov 2006 B2
7137963 Nita et al. Nov 2006 B2
7149587 Wardle et al. Dec 2006 B2
7150853 Lee et al. Dec 2006 B2
7166098 Steward et al. Jan 2007 B1
7220233 Nita et al. May 2007 B2
7267650 Chow et al. Sep 2007 B2
7297131 Nita Nov 2007 B2
7335180 Nita et al. Feb 2008 B2
7341569 Soltani et al. Mar 2008 B2
7384407 Rodriguez et al. Jun 2008 B2
7393338 Nita Jul 2008 B2
7421900 Karasawa et al. Sep 2008 B2
7425198 Moehring et al. Sep 2008 B2
7494468 Rabiner et al. Feb 2009 B2
7503895 Rabiner et al. Mar 2009 B2
7540852 Nita et al. Jun 2009 B2
7604608 Nita et al. Oct 2009 B2
7621902 Nita et al. Nov 2009 B2
7621929 Nita et al. Nov 2009 B2
7648478 Soltani et al. Jan 2010 B2
7758510 Nita et al. Jul 2010 B2
7771358 Moehring et al. Aug 2010 B2
7771452 Pal et al. Aug 2010 B2
7775994 Lockhart Aug 2010 B2
7776025 Bobo, Jr. Aug 2010 B2
7819013 Chan et al. Oct 2010 B2
7850623 Griffin et al. Dec 2010 B2
7918819 Karmarkar et al. Apr 2011 B2
7935108 Baxter et al. May 2011 B2
7938819 Kugler et al. May 2011 B2
7942809 Leban May 2011 B2
7955293 Nita et al. Jun 2011 B2
7993308 Rule et al. Aug 2011 B2
8038693 Allen Oct 2011 B2
8043251 Nita et al. Oct 2011 B2
8083727 Kugler et al. Dec 2011 B2
8133236 Nita Mar 2012 B2
8221343 Nita et al. Jul 2012 B2
8226566 Nita Jul 2012 B2
8246643 Nita Aug 2012 B2
8257378 O'connor Sep 2012 B1
8308677 Nita et al. Nov 2012 B2
8414543 Mcguckin, Jr. et al. Apr 2013 B2
8506519 Nita Aug 2013 B2
8613751 Nita et al. Dec 2013 B2
8617096 Nita et al. Dec 2013 B2
8632560 Pal et al. Jan 2014 B2
8641630 Nita et al. Feb 2014 B2
8647296 Moberg et al. Feb 2014 B2
8663259 Levine et al. Mar 2014 B2
8668709 Nita et al. Mar 2014 B2
8690818 Bennett et al. Apr 2014 B2
8690819 Nita et al. Apr 2014 B2
8764700 Zhang et al. Jul 2014 B2
8768433 Jenkins et al. Jul 2014 B2
8790291 Nita et al. Jul 2014 B2
8974446 Nguyen et al. Mar 2015 B2
8978478 Ishioka Mar 2015 B2
9101387 Plowe et al. Aug 2015 B2
9107590 Hansmann et al. Aug 2015 B2
9265520 Nita Feb 2016 B2
9282984 Nita Mar 2016 B2
9314258 Nita et al. Apr 2016 B2
9381027 Nita et al. Jul 2016 B2
9421024 Nita et al. Aug 2016 B2
9433433 Nita et al. Sep 2016 B2
9770250 Nita et al. Sep 2017 B2
9955994 Nita May 2018 B2
10004520 Nita et al. Jun 2018 B2
20020049409 Noda et al. Apr 2002 A1
20020077550 Rabiner et al. Jun 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020189357 Lai et al. Dec 2002 A1
20030009153 Brisken et al. Jan 2003 A1
20030036705 Hare et al. Feb 2003 A1
20030040762 Dorros et al. Feb 2003 A1
20030199817 Thompson et al. Oct 2003 A1
20030216732 Truckai et al. Nov 2003 A1
20030225332 Okada et al. Dec 2003 A1
20040019349 Fuimaono et al. Jan 2004 A1
20040024393 Nita et al. Feb 2004 A1
20040054367 Teodoro, Jr. et al. Mar 2004 A1
20040164030 Lowe et al. Aug 2004 A1
20040167511 Buehlmann et al. Aug 2004 A1
20040193033 Badehi et al. Sep 2004 A1
20050033311 Guldfeldt et al. Feb 2005 A1
20050149110 Wholey et al. Jul 2005 A1
20050165388 Bhola Jul 2005 A1
20050171527 Bhola Aug 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20060074441 Mcguckin, Jr. et al. Apr 2006 A1
20060149169 Nunomura et al. Jul 2006 A1
20060206039 Wilson et al. Sep 2006 A1
20060264809 Hansmann et al. Nov 2006 A1
20070032749 Overall et al. Feb 2007 A1
20080071343 Mayberry et al. Mar 2008 A1
20080208084 Horzewski et al. Aug 2008 A1
20080221506 Rodriguez et al. Sep 2008 A1
20080294037 Richter Nov 2008 A1
20090017293 Arai et al. Jan 2009 A1
20100004558 Frankhouser et al. Jan 2010 A1
20100023037 Nita et al. Jan 2010 A1
20100076454 Bos Mar 2010 A1
20100121144 Farhadi May 2010 A1
20110105960 Wallace May 2011 A1
20110130834 Wilson et al. Jun 2011 A1
20110196399 Robertson et al. Aug 2011 A1
20110196403 Robertson et al. Aug 2011 A1
20110237982 Wallace Sep 2011 A1
20110313328 Nita Dec 2011 A1
20120010506 Ullrich Jan 2012 A1
20120109021 Hastings et al. May 2012 A1
20120130475 Shaw May 2012 A1
20120311844 Nita et al. Dec 2012 A1
20120330196 Nita Dec 2012 A1
20130060169 Yamada Mar 2013 A1
20140236118 Unser et al. Aug 2014 A1
20140243712 Humayun et al. Aug 2014 A1
20140350401 Sinelnikov Nov 2014 A1
20150073357 Bagwell et al. Mar 2015 A1
20150105621 Farhadi Apr 2015 A1
20150105715 Pikus et al. Apr 2015 A1
20150133918 Sachar May 2015 A1
20150150571 Nita et al. Jun 2015 A1
20150157443 Hauser et al. Jun 2015 A1
20150190660 Sarge et al. Jul 2015 A1
20150297258 Escudero et al. Oct 2015 A1
20150359651 Wübbeling Dec 2015 A1
20160128717 Nita May 2016 A1
20160135835 Onuma May 2016 A1
20160183956 Nita Jun 2016 A1
20160271362 Van Liere Sep 2016 A1
20160328998 Nita et al. Nov 2016 A1
20160338722 Nita et al. Nov 2016 A1
20160367284 Nita et al. Dec 2016 A1
20170065288 Imai et al. Mar 2017 A1
20170354428 Nita et al. Dec 2017 A1
20180168668 Zheng Jun 2018 A1
20180177515 Boyle et al. Jun 2018 A1
20180221040 Roll Hoye Aug 2018 A1
20180280005 Parmentier Oct 2018 A1
20180280044 Nita et al. Oct 2018 A1
Foreign Referenced Citations (71)
Number Date Country
2007240154 Jan 2008 AU
2256127 May 1974 DE
2438648 Feb 1976 DE
8910040 Dec 1989 DE
3821836 Jan 1990 DE
4042435 Feb 1994 DE
10146011 Apr 2003 DE
0005719 Dec 1979 EP
0316789 May 1989 EP
0316796 May 1989 EP
0376562 Jul 1990 EP
0379156 Jul 1990 EP
0394583 Oct 1990 EP
0443256 Aug 1991 EP
0472368 Feb 1992 EP
0541249 May 1993 EP
0820728 Jan 1998 EP
1323481 Jul 2003 EP
1106957 Mar 1968 GB
H2-7150 Oct 1988 JP
01-099547 Apr 1989 JP
6086822 Mar 1994 JP
H07500752 Jan 1995 JP
7116260 May 1995 JP
9-503137 Mar 1997 JP
10-216140 Aug 1998 JP
2000-291543 Oct 2000 JP
2001-104356 Apr 2001 JP
2001-321388 Nov 2001 JP
2002-186627 Jul 2002 JP
2005-253874 Sep 2005 JP
2006-522644 Oct 2006 JP
2007512087 May 2007 JP
2007520255 Jul 2007 JP
3705739 Sep 1987 WO
3705793 Oct 1987 WO
8906515 Jul 1989 WO
9001300 Feb 1990 WO
9004362 May 1990 WO
9107917 Jun 1991 WO
9211815 Jul 1992 WO
9308750 May 1993 WO
9316646 Sep 1993 WO
9412140 Jun 1994 WO
9414382 Jul 1994 WO
9508954 Apr 1995 WO
9509571 Apr 1995 WO
9515192 Jun 1995 WO
9635469 Nov 1996 WO
9705739 Feb 1997 WO
9721462 Jun 1997 WO
9745078 Dec 1997 WO
9827874 Jul 1998 WO
9835721 Aug 1998 WO
9851224 Nov 1998 WO
9852637 Nov 1998 WO
9925412 May 1999 WO
0053341 Sep 2000 WO
0067830 Nov 2000 WO
02094103 Nov 2002 WO
03039381 May 2003 WO
2004012609 Feb 2004 WO
2004093736 Nov 2004 WO
2004112888 Dec 2004 WO
2005053769 Jun 2005 WO
2005112770 Dec 2005 WO
2006049593 May 2006 WO
2014022716 Feb 2014 WO
2014105754 Jul 2014 WO
2014106847 Jul 2014 WO
20180187159 Oct 2018 WO
Non-Patent Literature Citations (24)
Entry
Japanese Office Action for Japanese Application No. 2010-134566, dated Mar. 2, 2012.
Sehgal, et al., Ultrasound-Assisted Thrombolysis, Investigative Radiology, 1993, vol. 28, Issue 10, pp. 939-943.
Siegel, et al., “In Vivo Ultrasound Arterial Recanalization of Atherosclerotic Total Occlusions”, Journal of the American College of Cardiology, Feb. 1990, vol. 15, No. 2, pp. 345-351.
“What is Electron Beam Curing?” downloaded from web on Nov. 14, 2002, 4 pages total. <http://www.ms.oml.gov/researchgroups/composites/new%20orccmt%20pages/pages/ebwha>.
Noone, D.: Experimental and Numerical Investigation of Wire Waveguides for Therapeutic Ultrasound Angioplasty. M.Eng. Dublin City University. 2008.
Definition of the term “connected”, retrieved on Sep. 21, 2013. <www.thefreedictionary.com/connected> 1 page total.
Supplemental European Search Report dated Nov. 5, 2009 for European Application No. EP03766931.
International Search Report dated Oct. 28, 2003 for PCT Application No. PCT/US2003/023468.
Extended European Search Report dated Mar. 22, 2012 for European Application No. EP11188799.
International Search Report dated Dec. 23, 2005 for PCT Application No. PCT/US2004/019378.
Extended European Search Report for Patent Application No. 06718204.8, May 30, 2012.
International Search Report dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
International Preliminary Report dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
Written Opinion dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
Supplemental European Search Report dated Apr. 29, 2009 for European Application No. EP 04711207.3.
Extended European Search Report dated Mar. 5, 2012 for European Application No. 12153606.4-1269.
Margare Fyfe et al., Mast cell degranulation and increased vascular permeability induced by therapeutic' ultrasound in the rate ankle joint, Br. J. exp. Path., 1984, vol. 65, pp. 671-676.
“Irradiation, Biological, and Other Technologies: E-beam, Biological, and Sharps Treatment Systems”, Non-Incineration Medical Waste Treatment Technologies, Aug. 2001, Chapter 9, pp. 69-74, Health Care Without Harm, Washington, DC.
Paul Yock et al., Catheter-Based Ultrasound Thrombolysis Shake, Rattle, and Repertuse, https://doi.org/10.1161/01.CIR.95.6.1360 Circulation. 1997;95:1360-1362 Originally published Mar. 18, 1997.
Calhoun et al., “Electron-Beam Systems for Medical Device Sterilization”, downloaded from web on Oct. 8, 2002 <http://www.devicelink.com/mpb/archive/97/07/002.html> 7 pages total.
Definition of the term “coupled”, retrieved on May 18, 2013. <http://www.merriam-webster.com/dictionary/couple> 1 page total.
“E-Beam Theory” RDI-IBA Technology Group, downloaded from web on Oct. 8, 2002 <http://www.e-beamrdi/EbeamTheory.htm> 2 pages total.
Office Action dated May 20, 2010 from Japanese Application No. 2006-541200 filed on Oct. 25, 2004.
Office Action dated Oct. 11, 2012 from Japanese Application No. 2010-181956.
Related Publications (1)
Number Date Country
20190290304 A1 Sep 2019 US
Continuations (2)
Number Date Country
Parent 15413259 Jan 2017 US
Child 16437457 US
Parent 14365016 US
Child 15413259 US